Monoclonal antibody targets HLA-G in advanced cancers
A new clinical trial has launched to assess monoclonal antibody UCB4594 in people with advanced cancers.
The first site for the study has opened at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) at The Christie NHS Foundation Trust (The Christie) in Manchester.
Further sites across the UK are planned as the trial progresses.
UCB4594 works by targeting human leukocyte antigen G (HLA-G). HLA-G molecules are usually found on the surface of cells forming the placenta. The antigens interact with the immune system and influence the immune system’s ability to accept and support the growth of a foetus (a process called “maternal-foetal tolerance”).
As a foetus is genetically different from the mother, it would normally be treated as a foreign invader by the immune system, and maternal-foetal tolerance processes activate to counteract the normal immune response.
Certain types of cancer cells often take advantage of these processes by displaying HLA-G molecules on their surface to avoid being detected by the immune system.
Interfering with this process in non-pregnant patients is a potential way to prime the immune system to attack specific types of cancer cells with high levels of HLA-G molecules present.
Promising approach to beat cancer
Honorary Professor at The University of Manchester, Medical Oncology Consultant and Medical Director for the NIHR Manchester CRF at The Christie, Professor Fiona Thistlethwaite, who is leading the trial, said: “Despite many breakthroughs in cancer research, some cancers are still very challenging to treat, and patients deserve better treatment options. Targeting immune processes involving HLA-G could show promise as an approach for beating certain cancers. We look forward to seeing how this trial progresses to investigate whether UCB4594 is a tolerated and effective treatment for potentially treating patients with advanced cancers.”
The clinical development of UCB4594 is part of a multi-year, multi-project and multi-agent collaboration between UCB and Cancer Research UK’s Centre for Drug Development. Under the collaboration, Cancer Research UK are exclusively responsible for the design, sponsorship and delivery of the trial, while UCB will manufacture and provide UCB4594.
UCB retains exclusive rights to further develop and commercialise UCB4594 and will receive a licence to the results of the clinical trials from Cancer Research UK in return for undisclosed success-based milestone and royalty payments.
Director of Cancer Research UK’s Centre for Drug Development, Dr Lars Erwig, said: “We are grateful to our industry partners who license the use of their cutting-edge therapies. It enables Cancer Research UK’s Centre for Drug Development to sponsor and manage more trials, potentially bringing new treatments, like UCB4594, to patients sooner. We thank current and future participants involved in this early-stage clinical trial, and we look forward to seeing how the study progresses.”
Diana Spencer, Senior Digital Content Editor, DDW
